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Abstract 
 
The in vitro effect of the seminal vesicle protein IV (SV-IV) on the cytotoxic activity of human natural or acquired 
cellular immunity has been investigated by standard immunological procedures, a 
51
Cr-release cytotoxicity assay, and 
labeled-ligand binding experiments. The data obtained demonstrate that: 1) fluoresceinated or [
125
I]labeled SV-IV binds 
specifically  to the surface of human purified non-adherent monuclear cells (NA-MNC); 2) SV-IV suppresses the 
cytotoxicity of Natural Killer (NK) against K562 target cells, that of IL-2-stimulated NK (LAK) against DAUDI target 
cells, and that of VEL antigen-sensitized CTLs against VEL target cells; 3) treatment of K562 target cells alone with 
SV-IV decreases their susceptibility to NK-induced lysis. These findings, by indicating that the protein SV-IV has 
marked in vitro inhibitory effect on NK, LAK and CTL cytotoxicity, provide a better understanding of its immune 
regulatory functions.  
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1. Introduction  
SV-IV (seminal vesicle protein no. 4, according to its mobility in SDS-PAGE) is a small  (Mr = 
9,758), basic (pI = 8.9), highly thermostable, secretory protein synthesized in large amount by the 
rat seminal vesicle (SV) epithelium under strict androgen transcriptional control (Ostrowski et al., 
1979). Proteins immunorelated to SV-IV have also been found in several rat tissues (uterus, lung, 
liver, brain, etc.) and in human seminal fluid and SV secretion (Abrescia et al., 1985; Metafora et 
al., 1987a; Metafora et al., 1987b and unpublished results). SV-IV gene has been isolated, 
sequenced, cloned, and expressed in E. coli (D’Ambrosio et al., 1993). The mature protein, purified 
to homogeneity, has been extensively characterized (Ostrowski et al., 1979; Pan and Li, 1982; 
Kandala et al., 1983; Stiuso et al., 1999; Caporale et al., 2004). SV-IV is a highly flexible molecule 
whose biologically active configuration is monomeric, whereas its inactive one is trimeric (Stiuso et 
al., 1999; Caporale et al., 2004). The protein is biologically active between 2 and 30 M. Below the 
latter value the monomeric active population exceeds the inactive trimeric one with a maximum at 
about 10 M, while the opposite is true above this concentration (Stiuso et al., 1999; Caporale et al., 
2004).           
SV-IV possesses a nonspecies-specific ability to modulate inflammation and humoral and cell-
mediated immune response (Metafora et al., 1989; Peluso et al., 1994; Romano-Carratelli et al., 
1995; Tufano et al., 1996; Santagada et al., 2002),  to stimulate horseradish and Se-dependent 
peroxidases (Metafora et al., 2001 and unpublished data), to protect its target cells against oxidative 
stress-associated apoptosis  and, in particular, to defend nonself epididymal spermatozoa from  
immunological or reactive oxygen species (ROS) attacks in the female genital tract (Paonessa et al., 
1984; Morelli et al., 2007). The anti-inflammatory properties are related to phospholipase A2 (PLA2) 
inhibition (Metafora et al., 1989), whereas the pro-inflammatory features are based on SV-IV ability 
to stimulate mast-cell and basophil degranulation with concurrent release of histamine and other 
mediators (Metafora et al., manuscript in preparation). The modulation of immune response is 
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caused by interference of the protein with macrophage-T cell cooperation (Metafora et al., 1989; 
Peluso et al., 1994; Romano-Carratelli et al., 1995; Tufano et al., 1996; Santagada et al., 2002).  
Natural killer cells (NKs) and antigen-specific cytotoxic T lymphocytes (CTLs) are involved in 
host resistance to infections, immune surveillance against tumors, and rejection of transplanted 
tissues. NKs express on their surface specific markers (CD56 and CD16) and killer inhibitory 
receptors (KIR) (Yawata et al., 2006). These cells, in contrast with CTLs, are not MHC-restricted, 
even though their cytotoxic mechanisms are similar. Resting NKs express IL-2 receptors and 
respond to IL-2 acquiring enhanced cytotoxic function, recognizing a broader range of target cells 
(Moretta and Moretta, 2004) and taking the name of LAKs (lymphokine-activated killer cells).  
In mammals, insemination transmits into female reproductive tract a variety of seminal factors 
that promote sperm survival, condition the female immune response to tolerate the conceptus, and 
induce molecular and cellular endometrial changes to facilitate embryo development and 
implantation (Robertson, 2005). In particular, it is worth noting that in rat semen is present, in free 
and sperm-bound form, the antiapoptotic and immunomodulatory protein SV-IV, whereas SV-IV 
immunorelated proteins have been detected in human seminal plasma (Ostrowski et al., 1979; 
Paonessa et al., 1984; Abrescia et al., 1985; Metafora et al., 1987b; Manco et al., 1988).  
On the basis of these data and considerations, experiments were planned to verify whether SV-IV 
is able to exert its immunosuppressive activity on three models of human cell-mediated immune 
response not yet explored in detail by our group: a) the NK activity; b) the development  and  
cytotoxic activity of LAK cells; c) the generation and  cytotoxic activity of CTLs.  
  
2. Materials and methods 
2.1.  Purification of protein SV-IV 
The protein was purified to homogeneity from adult rat (Fisher-Wistar strain) seminal vesicle 
secretion according to a published procedure (Stiuso et al., 1999). A peculiar feature of SV-IV is the 
high thermoresistance: incubation in boiling water for 30-60 min neither precipitates the protein nor 
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changes its biological properties. The concentration of purified SV-IV was evaluated by its molar 
absorption at 276 nm (4100 M
-1
 cm
-1 
) (Stiuso et al., 1999; Caporale et al., 2004).  
 
2.2. Preparation of fluoresceinated SV-IV (SV-IVFITC) and its binding to human non-adherent 
mononuclear cells (NA-MNC) 
SV-IVFITC was prepared according to a conventional method (Goldman, 1968). Binding of SV-
IVFITC to NA-MNC (see below) was performed by mixing in the dark and at r.t. an appropriate number 
of cells suspended in PBS with an equal or 0.5 volume of 1.5 mg/ml (150 M) SV-IVFITC in PBS. Ten 
min later the cells were washed 3x with cold PBS and the binding of SV-IVFITC to cells was monitored 
with a Leitz Aristoplan light fluorescence microscope equipped with a suitable filter system for FITC 
fluorescence, a x40 objective, and a Leica camera. 
 
2.3.  Cell lines 
The NK- and LAK-susceptible human erythroleukemic MHC I 
–
 cell line K562,  the HLA class I 
deficient Burkitt lymphoma-derived cell line DAUDI, and the B-lymphoblastoid cell line VEL 
[transformed by Epstein–Barr virus (EBV) and kindly supplied by Dr. Stefano Vella,  Istituto 
Superiore di Sanità, Rome, Italy] were cultured in suspension in RPMI-1640 medium (Hyclone 
Europe, Cramlington, UK), supplemented with 10% fetal calf serum (FCS; Hyclone Laboratories, 
Logan, UT), 2 mM L-glutamine, and antibiotics (Life Technologies Ltd., Paisley, Scotland), and 
hereafter referred to as complete medium (CM). The cell lines were maintained at 37°C in 5% CO2 
humidified atmosphere and subcultured three times weekly. All target cells used were > 90% viable,
 
as measured by the Trypan Blue dye exclusion test and the carboxyfluorescein diacetate 
succinimidyl ester (CFSE) flow cytometry assay (Renovar, Inc., Madison, WI). 
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2.4. MNC, NK, LAK, and CTL preparation 
Peripheral blood mononuclear
 
cells (MNC), obtained from buffy-coats of healthy donors,
 
were 
prepared by Ficoll-Hypaque density centrifugation (Lympholyte-H, Cedarlane Laboratories 
Limited, Hornby,
 
Ontario, Canada). These experiments were approved by the Ethical Committee of  
the Blood Bank of the II Polyclinic Immuno-hematology Service (University Federico II, Naples, 
Italy). Adherent cells were removed by incubation
 
at 37° C for 1 h. The remaining non-adherent
 
cells (NA-MNC) were isolated by nylon wool columns.
 
The NKs occurring in this fraction were 
purified by a MACS
®
 two-step separation system (Miltenyi Biotech GmbH, Bergisch Gladbach,
 
Germany). The purified NKs were labeled with FITC-conjugated anti-NK antibodies, i.e. anti-CD16 
and anti-CD56 (Becton Dickinson, Mountain View, CA).
 
 The efficiency of separation and the total 
CD16
+
CD56
+
 NK counting were assessed by a FACScan  from Becton Dickinson. The yield was > 
95% with a purity of 97±1%. The viability (see above) of NKs  was > 95% in all the samples. The 
NK:T cells ratio in NA-MNC populations was evaluated by immuno-fluorescence flow cytometry, 
using specific cell surface markers for NKs (CD3
–
, CD16
+
, CD56
+
) and T cells (CD3
+
, CD16
–
, 
CD56
–
). 
To generate LAKs, NA-MNC were treated with recombinant human IL-2 (Roche, Basel, 
Switzerland), alone or in combination with SV-IV. To evaluate the effect of SV-IV on mature LAKs, 
these cells untreated or treated for 2 h with SV-IV were used as effector cells (called hereafter 
mature LAKs or mature LAKSV-IV, respectively) in cytotoxicity assays. Incubation of mature LAKs 
with SV-IV for 4 or 16 h did not change the results. The target cells used in LAK experiments were 
always 
51
Cr-labeled DAUDI cells. 
Allosensitized CTLs were generated by co-culturing for 5 days at 37°C MNC in presence of SV-
IV with mitomycin C-inactivated (80 g/ml) VEL cells at a MNC:VEL ratio of 40:1. 
Cell number and viability of MNC were evaluated at the beginning and at the end of  SV-IV 
treatment. After 2 or 120 h incubation, cell viability (see above) was higher than 97 ± 1.9 % in 
both control and SV-IV-treated cells.   
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2.5. 
51
Cr-release cytotoxicity assay 
The cytotoxic activity of NKs, LAKs, and CTLs was determined  using a 
51
Cr-release assay. 
Effector cells in 0.1 ml CM were plated in quadruplicate in U-bottomed 96-well microtiter 
plates (Greiner, Nurtingen, FRG) by making two-fold serial dilutions. Labeled target cells (2 x 
10
4
 in 0.1 ml) were added to give a final volume of 0.2 ml and an effector (E) to target (T) ratio 
ranging from 50:1 to 6.25:1. The plates were then centrifuged, incubated for 4 h at 37°C, 
recentrifuged, and 0.1 ml of supernatant from each well was counted by a gamma scintillation 
spectrometer (LKB, Sweden).  
The percentage of specific lysis was calculated as follows: 
      Test cpm – Autologous cpm 
                                 % Specific lysis  =  –––––––––––––––––––––––––––––– x 100 
                Total cpm 
 
where Test cpm is the mean cpm of 
51
Cr released from labeled target cells in the presence of 
effector cells, Autologous cpm is the mean cpm of 
51
Cr released from labeled target cells incubated 
with unlabeled autologous cells in place of effector cells, and Total cpm is the mean cpm 
corresponding to the total amount of 
51
Cr incorporated into the total of labeled target cells. 
 
2.6.  Conjugation assay 
 The percentage of target cells with bound lymphocytes was determined at two effector:target 
ratios, 50:1 and 25:1. The purified NKs were preincubated with appropriate concentrations of SV-IV 
for 2 h. Following the incubation period, the SV-IV-containing solution was removed by 
centrifugation and replaced with CM. K562 target cells were then incubated with a suitable number 
of control or SV-IV-treated NKs in U-bottomed 96-well microtiter plates (2 x 10
4
 tumor cells/well). 
Each experimental condition was tested in triplicate. The cells were incubated at 37° C, for 15 min, 
and then chilled on ice. Following incubation, the cells were gently resuspended with a micropipet, 
placed into a hemocytometer, and analyzed under a light microscope. The number of target cells with 
two or more lymphocytes bound to their surface and the total number of target cells were counted to 
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determine the percentage of tumor cells with bound lymphocytes. The minimum number of targets 
counted per determination was 100. The results of the SV-IV effect on the formation of clusters of 
fluorochrome-tagged NKs with K562 target cells obtained in a flow cytometry assay did not differ 
from the more simple optical method above described.  
 
2.7.  SV-IV negative controls used in the experiments 
 To rule out possible non-specific protein effects, we incorporated in our experimental design, 
where required, boiled and trypsinized SV-IV samples (2-30 M) as negative controls. Boiling was 
used to inactivate residual trypsin activity in the digested samples. The immunosuppressive activity 
of SV-IV was totally abolished by the trypsinization. Simply heat-treated SV-IV was not used as 
negative control because the heat treatment (100°C for 30-60 min) alone was unable to biologically 
inactivate the thermostable protein (see also “Purification of protein SV-IV” in this section).  
 
2.8.  [
125
I]SV-IV binding to purified human NA-MNC target cells 
The SV-IV binding mixture contained in a final volume of 0.3 ml: 10
7
 cells (NA-MNC), 140 mM 
NaCl, 50 mM Tris-HCl (pH 7.5), and 1.4 g of [125I]SV-IV (5x106 cpm) prepared by the chloramine 
T method (Hunter et al., 1978). After incubation, either at 37°C for 2 h or at 4° C for 30 min the 
assay mixtures were centrifuged (12,000xg at 4°C for 30 s) and the sedimented cells washed with 
RPMI 1640 until no radioactivity was detectable in supernatant. The washed cells were transferred 
before lysis in another polypropylene test tube to avoid contamination of final cell lysate with 
radioactivity not bound to the cells but adsorbed to the assay test tube walls. Cell lysis was carried 
out by suspending each cell pellet in 60 l of double distilled water. After addition of 30 l of a 
solution containing 15% -mercaptoethanol, 190 mM Tris-HCl buffer (pH 6.8), and glycerol, the 
samples were boiled for 2 min and then analyzed by TCA-precipitable radioactivity counting and 
SDS-15% PAGE (Metafora et al., 1987a). 
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2.10.  Statistical analysis  
Differences in cytolytic effects produced by NK, LAK, and CTL effectors under various 
experimental conditions were evaluated by taking into account the % specific cytotoxicity at all E:T 
ratios. Therefore, P values were calculated using co-variance analysis performed on the regression 
of the percentage of specific 
51
Cr release over the log of the number of effector cells. 
Binding and cytotoxicity assay data were expressed as the mean  standard error of the mean  
(SEM) obtained from 3 separate experiments. Each binding experiment included 9 samples; each 
sample was performed in triplicate. In cytotoxicity assays each point was carried out in 
quadruplicate. One-way analysis of variance (ANOVA) was used to assess statistical significance 
between means. Differences between means were considered significant when P < 0.05 using the 
Bonferroni post-test. All statistical analyses were performed with the GraphPad Instant software 
(Intuitive Software for Science, San Diego, CA). 
 
3.  Results  
3.1.  Inhibitory activity of SV-IV on NK cytotoxicity against K562 target cells 
   To evaluate the effect of SV-IV on NK function, purified NKs were exposed to various 
concentrations of SV-IV for 16 h in CM before the 
51
Cr release assay, in which SV-IV-untreated 
51
Cr-labeled K562 cells were used as target. The result of a representative experiment, concerning 
one out of five purified NK samples obtained from five different donors, is reported in Fig. 1A. The 
treatment with SV-IV shows a significant (P<0.05) and concentration-dependent inhibition of NK 
cytotoxic activity. Cell number (2 x 10
4
 target cells) and viability (about 96%), assessed at the 
beginning and at the end of the incubation period with SV-IV, did not vary significantly among the 
various experimental conditions used.   
Similar suppressive effect (P<0.05) on NK activity was found  when K562 target cells alone were 
treated with 10 or 25 M SV-IV for the same length of time (16 h) (Fig. 1B). Results did not differ 
when Raji cells were used as target cells in place of K562 (data not shown). 
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To investigate the effect of SV-IV on effector/target cell interaction, the 4 h cytotoxicity assay 
was performed by treating the effector/target mixture with 10 M SV-IV. The data from a 
representative experiment reported in Fig. 1C show that the percentage of lysis of K562 target cells 
produced by intact purified NKs was significantly (P<0.05) reduced by  SV-IV.  
Additional experiments were performed to evaluate the effect of SV-IV on the conjugation 
process between purified NKs and K562 target cells.  The results demonstrated that 10 M SV-IV 
inhibited (P<0.05) by about 48% (mean value) the NK binding to K562. 
 
3.2.  The functional activity of IL-2-stimulated NKs  is suppressed by SV-IV 
To evaluate the effect of SV-IV on the generation and lytic function of IL-2-activated NKs, NA-
MNC were exposed for 2, 4 or 16 h to 5 M SV-IV either before or after 4 days of culture with IL-2 
and then tested for cytotoxic activity against 
51
Cr-labeled DAUDI target cells. The result of a 
representative experiment (Fig. 1D) demonstrates that SV-IV does not affect (P<0.05) the LAK 
generation. In contrast, the cytotoxic  activity of cells treated with SV-IV for 16 h after IL-2 
stimulation (LAKSV-IV) was significantly (P<0.05) inhibited (Fig. 1E). Similar results were obtained 
when LAKs were treated  with SV-IV for 2 or 4 h.  
 
3.3.  The alloantigen-induced generation of CTLs is decreased by SV-IV 
To assess the effect of SV-IV on CTL induction, NI-MNC (Non Immunized-MNC) were 
stimulated for 5 days (day 1-5) with mitomycin C-inactivated VEL target cells. Five M SV-IV was 
added or not (controls) to both NI- and I (Immunized)-MNC cultures on day 1. On day 5, the 
effectors were harvested, washed, and evaluated for CTL activity against 
51
Cr-labeled VEL cells. 
The results of a representative experiment concerning 5 samples from different donors (Fig. 1F) 
show that the protein produced a statistically significant (P<0.05) reduction of CTL activity.  
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3.4.  SV-IVFITC and [
125
I]SV-IV binding to the surface of human purified NA-MNC 
The treatment of NA-MNC cells at r.t. with 15 M SV-IVFITC generated a nonhomogeneous 
fluorescent coat on their surface (Fig. 2).These data are consistent with similar binding observations 
already published (Metafora et al., 1989; Morelli et al., 2007). 
Native  [
125
I]SV-IV was incubated with NA-MNC to evaluate the number of specific SV-IV 
binding sites occurring on the surface of these cells. The low temperature used (4°C; see Materials 
and Methods) was chosen in order to avoid internalization of the protein during the binding assay. 
Scatchard analysis of radioactivity bound to cell surface either in presence or in absence of native or 
trypsinized unlabeled SV-IV, or other unlabeled proteins [BSA or proteins (histones, cyt-c)  with a 
Mr and a pI similar to that of SV-IV], showed the specificity of this binding. The binding sites 
contained only saturable components displaceable in a dose-dependent manner only by unlabeled 
native or trypsinized SV-IV and not by unlabeled BSA, histones or cyt-c. The number of specific 
binding sites, calculated by Scatchard analysis, was 1 ± 0.2 x 10
5
/cell (P<0.05) with a Kd of  1 ± 0.5 
x 10
-8
 M (P<0.05). These results fully confirmed previously published binding data of SV-IV to its 
target cells (Stiuso et al., 1999; Romano-Carratelli et al., 2002). The binding at 37°C was found 
about 25% lower, probably as consequence of a slight release of counts from cell surface caused by 
the relatively high Kd. Additional experiments proved that the labeled protein (FITC- or iodinated-
SV-IV) remained structurally (SDS-PAGE) intact into medium up to 4 days incubation at 37°C. 
Other data indicate that the putative SV-IV receptors probably signal via a protein tyrosine kinase-
operated pathway (Morelli et al., 2007). 
 
4. Discussion 
The results reported in this paper show that SV-IV inhibits  in vitro the cytolytic effects of human 
NK, LAK, and antigen-activated CTL effectors, whereas the treatment of target cells alone with the 
protein decreases their susceptibility to NK-induced lysis. These data confirm the 
immunosuppressive activity of SV-IV previously observed in other experimental settings (Paonessa 
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et al., 1984; Metafora et al., 1989; Peluso et al., 1994; Romano-Carratelli et al., 1995; Romano-
Carratelli et al., 2002).  
The concentration of SV-IV used was in the 2-15 M range, a value comparable to physiological 
levels. In fact, in the rat female reproductive tract following coitus the SV-IV concentration ranges 
between 12 and 48 M, whereas the concentration in the aqueous extracts of other organs (liver, 
brain, lung, uterus, etc.) is lower, ranging from 2 to 10 M (Stiuso et al., 1999). It is worth noting 
that at these concentrations SV-IV is mainly monomeric and its biological activity is maximal 
(Stiuso et al., 1999).  
To exclude that the inhibition of cell-mediated immunity by SV-IV (see above) was due to 
generic toxicity, its effect on morphology, viability, and proliferation of resting and IL-2-stimulated 
NKs was analysed. In comparison to untreated samples, no changes in morphology and viability 
were observed in SV-IV-treated cells up to 2 h and 4-5 days of culture. Similar results were 
obtained with resting or antigen-stimulated CTLs. In addition, the possibility that the 
immunosuppression was due to aspecific cytotoxic properties can be ruled out by the following 
observations: 1) immunosuppression was detectable on activated MNC (see Results) only at low 
concentrations (5 to 30 M), rich in biologically active SV-IV monomers; at similar low 
concentrations SV-IV did not inhibit but, in contrast, stimulated quiescent lymphocytes to 
synthesize and release specific cytokines (Tufano et al., 1996); 2) at concentrations higher than 30 
M, rich in biologically inactive SV-IV trimers, no cytotoxic effects were observed (Stiuso et al., 
1999); 3) the inhibitory effects of SV-IV on proliferation were found only for immunocompetent 
cells (Metafora et al., 1989); 4) in addition, SV-IV has been recently demonstrated to possess 
intrinsic antiapoptotic activity (Morelli et al., 2007). 
Our studies raise the possibility that SV-IV could be active in preventing lymphocyte cytotoxicity 
towards implanting embryos also in vivo. Although a direct evidence of this is missing, we have 
demonstrated that SV-IV-immunorelated proteins are present (standard competition RIA and SDS-
15% PAGE) in rat uterus (uterine fluid, endometrium, and decidua lysates) after insemination 
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(Metafora et al., 1987a and unpublished results). In humans, however, data on the occurrence in 
uterus of SV-IV-immunorelated proteins are not available at present, even though we have found 
these type of proteins in human SV secretion and seminal fluid (Metafora et al., 1987b). 
Experiments are in progress to acquire further information on this point. 
In our experimental design the possible protective effect of SV-IV against maternal cell-mediated 
immune response and ROS attacks on implanting hemi-allogeneic blastocysts has been evaluated in 
vitro by using human peripheral blood NKs rather than decidual NK cells: this is an imperfect 
model (as are all models), but the phenomenon described seems to be interesting regardless the 
source of the NKs tested . 
Fig.1D shows that SV-IV does not influence LAK generation probably because the activation of 
NKs by IL-2 is either insensitive to SV-IV or, alternatively, is subjected to  unknown control 
mechanisms during in vitro culture. This finding is consistent with the fact that IL-2 is poorly 
represented at fetal-maternal interface in the implantation site, where LAKs are few (King and 
Loke, 1990) and probably also immunosuppressed by uterine SV-IV (Stiuso et al., 1999), 
uteroglobin (Mukherjee et al., 2007), and some other factor (TGF -1, IL-10, decidual TReg and T 
cells, etc.).  This is in line with the fact that mature LAKs exposed to SV-IV on day 4 for only 2 h, 
immediately before the cytotoxicity assay, showed a reduction of their cytolytic potential (Fig. 1E).  
The hemi-allogeneic mammal early embryo has to face at its uterine implanting site the maternal 
innate and acquired immune alloreactivity and possible ROS attacks. The blastocyst, however, is 
well equipped to counteract this harmful situation. Synthesis of HLA-G as a substitute of missing 
HLA class I, allows blastocysts not only to silence uNK and CTL anti-blastocyst cytotoxicity, but 
also to obtain uNK cooperation for embryo development by inducing these cells to secrete 
embryotrophic cytokines and factors promoting cell growth, angiogenesis, and EVT survival and 
invasiveness (Rouass-Freis et al., 1997; Moretta and Moretta, 2004; Perham, 2004; Rajagopalan et 
al., 2006). In addition, the occurrence in uterus at blastocyst implanting time of a high number of 
protective molecules (Leukemia Inhibitory Factor, heme oxygenase HO-1, IL-10, TGF-, etc.), 
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tolerogenic CD4
+
CD25
+
Foxp3
+
 TReg cells (Zenclussen et al., 2006), and mast cells (Dey et al., 
2004), together with the recent finding in long–term allograft tolerance systems of a novel TReg-IL-
9-mast cell immunosuppressive relationship [TReg (TGF-)  IL-9  mast cell  (TGF-)] (Lu et 
al., 2006; Zenclussen et al., 2006;), is of substantial help for the formation of an immunotolerant and 
antiapoptotic implantation site. The presence of  SV-IV in the uterus at this location following 
insemination could also contribute to the definition of the immunotolerant characteristics of the site, 
although the evidence that the protein is present in this location at the implantation time is only 
circumstantial (SV-IV is present in rat ejaculated semen in free and sperm-bound form; an SV-IV 
immunorelated protein has been found in rat uterine lysates and in human seminal plasma) 
(Ostrowski et al., 1979; Paonessa et al., 1984; Abrescia et al., 1985; Metafora et al., 1987a; 
Metafora et al., 1987b and unpublished results from our lab; Manco et al., 1988). In rats, this 
speculation seems supported by mixed cell culture experiments [maternal splenocytes (responder 
cells) co-cultured with mitomycin-C-inactivated hemi-allogeneic blastomeres, isolated from 
implanting blastocyst and treated or not with 5 M SV-IV] performed in our laboratory and 
demonstrating that the immunogenicity of blastocyst blastomeres, as evaluated by the [
3
H]thymidine 
incorporation assay, is suppressed (about 80%) in presence of SV-IV (SV-IV-untreated blastomeres: 
12,800 cpm ± 400 cpm; SV-IV-treated blastomeres: 2350 ± 220 cpm; splenocyte only: 230 ± 75 
cpm; splenocyte plus Con A: 31,000 ± 1200 cpm). These SV-IV-induced immunosuppressive 
findings are in line with the protective effect of SV-IV on Raji, K562, and Daudi target cells against 
the NK cytotoxicity (see Results). In this setting it appears also relevant: 1) the SV-IV ability to 
activate mast cell degranulation with release of immunosuppressive and antiapoptotic histamine  
and TGF- (Hansson et al., 1999; Metafora et al., manuscript in preparation); 2) the SV-IV ability to 
protect mouse zygote growth up to blastocyst stage in the semi-solid Fell and Robison culture 
medium nonpermissive for fertilized egg early development (Morelli et al., 2007). 3) other data 
showing the critical role of oxidative stress in jeopardizing embryo survival during early 
development (Guerin et al., 2001).  
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In conclusion, the experimental results reported in this paper, when analysed in the context of 
other published biological features of SV-IV, not only provide a better understanding of its immune 
regulatory functions, but raise also the possibility of a contributory role (at least in rodents) in the 
multifactorial orchestration at the uterine implantation site of maternal immunotolerance and 
blastocyst survival. More convincing data on SV-IV presence at the uterine implantation site and 
specific in vivo experiments (e.g. null mutation of SV-IV gene) are, however, demanded to provide 
conclusive evidence for this role.  
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LEGENDS TO FIGURES 
 
Figure 1. Effect of SV-IV on the cytotoxic activity of purified NK cells using K562 as target cells: 
(A) inhibitory effect on SV-IV-treated NK cells; (B) inhibitory effect on SV-IV-treated K562 cells; 
(C) inhibitory effect on SV-IV-treated effector-target cell mixture. Inhibitory effect of SV-IV on 
LAK cell cytotoxicity: (D) during the LAK generation phase; (E) on mature LAKs. Inhibitory effect 
of SV-IV on CTL generation: (F) MNC were stimulated for 5 days (day 1-5) with mytomicin C-
inactivated VEL cells. Five M SV-IV was added to MNC cultures on day 1. On day 5, the VEL-
sensitized CTL effector cells were harvested, washed, and evaluated for cytotoxic activity. 
Experimental details are in Material and Methods. Error bars indicate SEM.  
 
Figure 2. Binding of fluoresceinated SV-IV to NA-MNC cell surface. Experimental details are in 
Material and Methods. 
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Abstract  
The in vitro effect of seminal vesicle protein IV (SV-IV) on the cytotoxic activity of human natural 
or acquired cellular immunity has been investigated by standard immunological procedures, a 51Cr-
release cytotoxicity assay, and labeled-ligand binding experiments. The data obtained demonstrate 
that: (1) fluoresceinated or [125I]-labeled SV-IV binds specifically to the surface of human purified 
non-adherent monuclear cells (NA-MNC); (2) SV-IV suppresses the cytotoxicity of natural killer 
(NK) cells against K562 target cells, that of IL-2-stimulated NK (LAK) cells against DAUDI target 
cells, and that of VEL antigen-sensitized cytotoxic T lymphocytes (CTLs) against VEL target cells; 
(3) treatment of K562 target cells alone with SV-IV decreases their susceptibility to NK-induced 
lysis. These findings indicate that the protein SV-IV has a marked in vitro inhibitory effect on NK, 
LAK and CTL cytotoxicity, providing a better understanding of its immune regulatory functions. 
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